FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386840699> ?p ?o ?g. }

• W4386840699 endingPage "127300" @default.
• W4386840699 startingPage "127300" @default.
• W4386840699 abstract "Inflammation and oxidative stress crosstalk is involved in the ischemic stroke(IS) pathogenesis and the new therapeutic options should be offered based on the targets that are critical in the golden hour of IS. YKL-40 and total antioxidant capacity(TAC), the inflammation and oxidative stress biomarkers, provide us with clues for proper intervention targets. N-acetyl cysteine amide (NACA), a lipophilic antioxidant, with a nanoparticle-based drug delivery system is permeable enough to penetrate blood-brain barrier (BBB) and was proposed as a new treatment option for IS. In this study, we evaluated the YKL-40 and TAC levels in the sera of IS patients to elucidate the best intervention target. A rat tissue model is used to assess the NACA efficiency. The microbiology tests performed to figure out the potential NACA and antibiotics interactions.The YKL-40 and TAC were measured in the serum of IS patients by ELISA and FRAP methods, respectively. The serum samples were obtained 12 h after the patient's admission and meantime other laboratory findings and NIHSS-based prognosis were recorded. In the animal study, the brain cortex, liver, kidney, adipose, and the heart of healthy rats were dissected and then incubated in DMEM cell culture media containing 50 micrograms/milliliter of nanoparticles; the nanoparticles were titanium dioxide nanoparticles (TiO2 NPs), copper oxide nanoparticles (CuO NPs) and cerium dioxide nanoparticles (CeO2 NPs). Olive oil and human serum albumin solution were exposed to the nanoparticles with and without NACA. TAC was measured in the supernatant culture media. With similar concentrations and settings, we evaluated the NACA, nanoparticle, and antibiotics interactions on pseudomonas aeruginosa.There was a nonparametric correlation between YKL-40 levels and post stroke serum TAC levels. Nonsmokers had higher YKL-40 and TAC levels than smokers. A new calculated variable, urea*lymphocyte/age, predicts a poor prognosis with an acceptable AUC (0.708). Exposing to the nanoparticles, the liver, kidney, and brain had a significantly higher TAC than adipose and cardiac tissue. The NACA had an ameliorative effect against TiO2 NPs in the brain. This effectiveness of NACA was also observed against CuO NPs treatment. However, the CeO2 NPs exert a strong antioxidant property by reducing the TAC in the brain tissue but not the others. Albumin showed antioxidant properties by itself, but olive oil had an inert behavior. NACA had no interaction with the action of routine antibiotics.Oxidative stress but not inflammation is the best point for intervention in IS patients because YKL-40 has not a relationship with NIHSS score. The CeO2 NPs and NACA combination are eligible option to develop antioxidant-based drug for the treatment of IS. As a complementary finding, the urea*lymphocyte/age is proposed as a NIHSS-based prognosis biomarker." @default.
• W4386840699 created "2023-09-19" @default.
• W4386840699 creator A5012059183 @default.
• W4386840699 creator A5047503716 @default.
• W4386840699 creator A5053802210 @default.
• W4386840699 creator A5086256777 @default.
• W4386840699 creator A5089493985 @default.
• W4386840699 creator A5092897442 @default.
• W4386840699 creator A5092897443 @default.
• W4386840699 creator A5092897444 @default.
• W4386840699 date "2023-12-01" @default.
• W4386840699 modified "2023-09-30" @default.
• W4386840699 title "N-Acetyl cysteine amide and Cerium Oxide Nanoparticles as a Drug Delivery for Ischemic Stroke Treatment; Inflammation and Oxidative Stress Crosstalk" @default.
• W4386840699 cites W1564553363 @default.
• W4386840699 cites W1977844958 @default.
• W4386840699 cites W1980633206 @default.
• W4386840699 cites W1987047406 @default.
• W4386840699 cites W1988001171 @default.
• W4386840699 cites W2007790334 @default.
• W4386840699 cites W2019099022 @default.
• W4386840699 cites W2027072680 @default.
• W4386840699 cites W2042313213 @default.
• W4386840699 cites W2050258051 @default.
• W4386840699 cites W2061779708 @default.
• W4386840699 cites W2074571664 @default.
• W4386840699 cites W2077881367 @default.
• W4386840699 cites W2087411027 @default.
• W4386840699 cites W2090732472 @default.
• W4386840699 cites W2111356633 @default.
• W4386840699 cites W2123052816 @default.
• W4386840699 cites W2133387761 @default.
• W4386840699 cites W2142066097 @default.
• W4386840699 cites W2146122787 @default.
• W4386840699 cites W2154899903 @default.
• W4386840699 cites W2155543365 @default.
• W4386840699 cites W2157766903 @default.
• W4386840699 cites W2371948111 @default.
• W4386840699 cites W2417663854 @default.
• W4386840699 cites W2743230035 @default.
• W4386840699 cites W2913787533 @default.
• W4386840699 cites W2934987465 @default.
• W4386840699 cites W2963744228 @default.
• W4386840699 cites W3025871009 @default.
• W4386840699 cites W3035191411 @default.
• W4386840699 cites W3043771868 @default.
• W4386840699 cites W3163192871 @default.
• W4386840699 cites W3175419278 @default.
• W4386840699 cites W3203141221 @default.
• W4386840699 doi "https://doi.org/10.1016/j.jtemb.2023.127300" @default.
• W4386840699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37741051" @default.
• W4386840699 hasPublicationYear "2023" @default.
• W4386840699 type Work @default.
• W4386840699 citedByCount "0" @default.
• W4386840699 crossrefType "journal-article" @default.
• W4386840699 hasAuthorship W4386840699A5012059183 @default.
• W4386840699 hasAuthorship W4386840699A5047503716 @default.
• W4386840699 hasAuthorship W4386840699A5053802210 @default.
• W4386840699 hasAuthorship W4386840699A5086256777 @default.
• W4386840699 hasAuthorship W4386840699A5089493985 @default.
• W4386840699 hasAuthorship W4386840699A5092897442 @default.
• W4386840699 hasAuthorship W4386840699A5092897443 @default.
• W4386840699 hasAuthorship W4386840699A5092897444 @default.
• W4386840699 hasConcept C126322002 @default.
• W4386840699 hasConcept C155672457 @default.
• W4386840699 hasConcept C171250308 @default.
• W4386840699 hasConcept C178790620 @default.
• W4386840699 hasConcept C185592680 @default.
• W4386840699 hasConcept C192562407 @default.
• W4386840699 hasConcept C2776151105 @default.
• W4386840699 hasConcept C2776914184 @default.
• W4386840699 hasConcept C2778004101 @default.
• W4386840699 hasConcept C2779820397 @default.
• W4386840699 hasConcept C55493867 @default.
• W4386840699 hasConcept C71924100 @default.
• W4386840699 hasConcept C98274493 @default.
• W4386840699 hasConceptScore W4386840699C126322002 @default.
• W4386840699 hasConceptScore W4386840699C155672457 @default.
• W4386840699 hasConceptScore W4386840699C171250308 @default.
• W4386840699 hasConceptScore W4386840699C178790620 @default.
• W4386840699 hasConceptScore W4386840699C185592680 @default.
• W4386840699 hasConceptScore W4386840699C192562407 @default.
• W4386840699 hasConceptScore W4386840699C2776151105 @default.
• W4386840699 hasConceptScore W4386840699C2776914184 @default.
• W4386840699 hasConceptScore W4386840699C2778004101 @default.
• W4386840699 hasConceptScore W4386840699C2779820397 @default.
• W4386840699 hasConceptScore W4386840699C55493867 @default.
• W4386840699 hasConceptScore W4386840699C71924100 @default.
• W4386840699 hasConceptScore W4386840699C98274493 @default.
• W4386840699 hasLocation W43868406991 @default.
• W4386840699 hasLocation W43868406992 @default.
• W4386840699 hasOpenAccess W4386840699 @default.
• W4386840699 hasPrimaryLocation W43868406991 @default.
• W4386840699 hasRelatedWork W1490540217 @default.
• W4386840699 hasRelatedWork W1991687135 @default.
• W4386840699 hasRelatedWork W2022293772 @default.
• W4386840699 hasRelatedWork W2051881276 @default.
• W4386840699 hasRelatedWork W2061572524 @default.
• W4386840699 hasRelatedWork W2748952813 @default.

• next